EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

"Honestly, I'm quite alarmed by what we see in the U.S. now," Novo Nordisk President and CEO Lars Fruergaard Jorgensen told ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...

Indian biotechnology and pharmaceutical companies Biocon Ltd and Dr. Reddy's Laboratories Ltd have improved their standings ...

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...